Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2021 Filed Sep 3, 2021 21:12 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 1,805 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008256 · form4.xml · derivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415 Underlying: Bio-Rad A Common Stock · 1,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:12 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad A Common Stock | 895 | $825.77 | $739,064.15 |
DisclosureSEC source: 0001062993-21-008256 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,881 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:12 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad A Common Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008256 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionRestricted Stock Units · Derivative | 433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Tax withholdingBio-Rad A Common Stock | 150 | $825.77 | $123,865.50 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382.3476 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:10 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008254 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,532.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:09 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008252 · form4.xml · derivative · entry 5 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:09 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Tax withholdingBio-Rad A Common Stock | 215 | $825.77 | $177,540.55 |
DisclosureSEC source: 0001062993-21-008252 · form4.xml · nonDerivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,887 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:09 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionBio-Rad A Common Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008252 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:08 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionRestricted Stock Units · Derivative | 433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008249 · form4.xml · derivative · entry 5 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Bio-Rad A Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,733 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:08 UTC |
WRIGHT DARAExecutive Vice President
|
Tax withholdingBio-Rad A Common Stock | 150 | $825.77 | $123,865.50 |
DisclosureSEC source: 0001062993-21-008249 · form4.xml · nonDerivative · entry 2 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:08 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008249 · form4.xml · nonDerivative · entry 1 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:07 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008247 · form4.xml · derivative · entry 4 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Bio-Rad A Common Stock · 240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 963 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 963 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:07 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Tax withholdingBio-Rad A Common Stock | 83 | $825.77 | $68,538.91 |
DisclosureSEC source: 0001062993-21-008247 · form4.xml · nonDerivative · entry 2 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390.3993 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:07 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionBio-Rad A Common Stock | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008247 · form4.xml · nonDerivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473.3993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 11.7355 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 902 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · derivative · entry 10 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Bio-Rad A Common Stock · 902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F10 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F10 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 448 | $825.77 | $369,944.96 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 6 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,735.9181 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 902 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 5 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,183.9181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:01 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionRestricted Stock Units · Derivative | 361 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008240 · form4.xml · derivative · entry 5 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083 Underlying: Bio-Rad A Common Stock · 361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:01 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Tax withholdingBio-Rad A Common Stock | 125 | $825.77 | $103,221.25 |
DisclosureSEC source: 0001062993-21-008240 · form4.xml · nonDerivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155.0531 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:01 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionBio-Rad A Common Stock | 361 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008240 · form4.xml · nonDerivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280.0531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 541 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · derivative · entry 9 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Bio-Rad A Common Stock · 541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 540 | $0.00 Strike: $524.30 | $0.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · derivative · entry 8 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626 Underlying: Bio-Rad A Common Stock · 540 shares Expires 2030-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 2,166 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 269 | $825.77 | $222,132.13 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 541 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
SaleBio-Rad A Common Stock | 100 | $828.01 | $82,801.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
SaleBio-Rad A Common Stock | 440 | $828.00 | $364,320.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 540 | $524.30 | $283,122.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:12 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,064 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008256 · form4.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,064 Underlying: Bio-Rad A Common Stock · 5,064 shares Expires 2031-09-01 F6 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:12 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantRestricted Stock Units · Derivative | 5,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008256 · form4.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,064 Underlying: Bio-Rad A Common Stock · 5,064 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:09 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,621 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008252 · form4.xml · derivative · entry 4 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 Underlying: Bio-Rad A Common Stock · 1,621 shares Expires 2031-09-01 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:09 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
GrantRestricted Stock Units · Derivative | 1,621 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008252 · form4.xml · derivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 Underlying: Bio-Rad A Common Stock · 1,621 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:08 UTC |
WRIGHT DARAExecutive Vice President
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,621 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008249 · form4.xml · derivative · entry 4 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 Underlying: Bio-Rad A Common Stock · 1,621 shares Expires 2031-09-01 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:08 UTC |
WRIGHT DARAExecutive Vice President
|
GrantRestricted Stock Units · Derivative | 1,621 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008249 · form4.xml · derivative · entry 3 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 Underlying: Bio-Rad A Common Stock · 1,621 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:07 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
GrantRestricted Stock Units · Derivative | 676 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008247 · form4.xml · derivative · entry 3 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676 Underlying: Bio-Rad A Common Stock · 676 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $299.24 | $0.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · derivative · entry 9 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 2,000 shares Expires 2029-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,532 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · derivative · entry 8 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,532 Underlying: Bio-Rad A Common Stock · 2,532 shares Expires 2031-09-01 F8 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
GrantRestricted Stock Units · Derivative | 2,532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · derivative · entry 7 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,532 Underlying: Bio-Rad A Common Stock · 2,532 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F7 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
SaleBio-Rad A Common Stock | 599 | $814.09 | $487,639.91 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 4 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281.9181 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
SaleBio-Rad A Common Stock | 651 | $813.15 | $529,360.65 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,880.9181 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
SaleBio-Rad A Common Stock | 750 | $812.27 | $609,202.50 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,531.9181 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:05 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 2,000 | $299.24 | $598,480.00 |
DisclosureSEC source: 0001062993-21-008244 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,281.9181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,013 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008240 · form4.xml · derivative · entry 4 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013 Underlying: Bio-Rad A Common Stock · 1,013 shares Expires 2031-09-01 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:01 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
GrantRestricted Stock Units · Derivative | 1,013 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008240 · form4.xml · derivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013 Underlying: Bio-Rad A Common Stock · 1,013 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,823 | $0.00 Strike: $814.95 | $0.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · derivative · entry 7 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823 Underlying: Bio-Rad A Common Stock · 1,823 shares Expires 2031-09-01 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:02 UTC |
Daskal IlanEVP, Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 1,823 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008242 · form4.xml · derivative · entry 6 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823 Underlying: Bio-Rad A Common Stock · 1,823 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 14:39 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 600 | $792.58 | $475,548.00 |
DisclosureSEC source: 0001062993-21-007992 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,099.3476 Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001062993-21-007240 · form4.xml · derivative · entry 4 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 3,000 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 11, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 430 | $755.72 | $324,959.60 |
DisclosureSEC source: 0001062993-21-007240 · form4.xml · nonDerivative · entry 3 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $755.52 to $756.30, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 2,570 | $754.80 | $1,939,836.00 |
DisclosureSEC source: 0001062993-21-007240 · form4.xml · nonDerivative · entry 2 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,099 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $754.52 to $755.39, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.